P Gascon1, U Fuhr2, F Sörgel3, M Kinzig-Schippers4, A Makhson5, S Balser6, S Einmahl7, M Muenzberg8. 1. Division of Medical Oncology, Hospital Clinic, Barcelona University, Barcelona, Spain. 2. Department of Pharmacology, University Hospital, University of Cologne, Cologne, Germany; Itecra GmbH & Co. KG, Cologne, Germany. 3. IBMP - Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany; Department of Pharmacology, University of Duisburg-Essen, Essen, Germany. 4. IBMP - Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany. 5. Moscow City Oncology Hospital, Moscow, Russia. 6. Sandoz International GmbH, Holzkirchen, Germany. 7. Triskel Integrated Services, Geneva, Switzerland. 8. Sandoz International GmbH, Holzkirchen, Germany. Electronic address: michael.muenzberg@sandoz.com.
Abstract
BACKGROUND:Zarzio, a new recombinant human granulocyte colony-stimulating factor (filgrastim), was evaluated in healthy volunteers and neutropenic patients in phase I and III studies. PATIENTS AND METHODS: Healthy volunteers in randomized, two-period crossover studies received single- and multiple-dose s.c. injections of 1 microg/kg (n = 24), 2.5 microg/kg (n = 28), 5 microg/kg (n = 28), or 10 microg/kg (n = 40), as well as single-dose i.v. infusions of 5 microg/kg (n = 26), of Zarzio or the reference product (Neupogen). Filgrastim serum levels were monitored; pharmacodynamic parameters were absolute neutrophil count (all studies) and CD34(+) cells (multiple-dose studies). Supportive efficacy and safety data were obtained from an open phase III study in 170 breast cancer patients undergoing four cycles ofdoxorubicin and docetaxel (Taxotere) chemotherapy, receiving Zarzio (300 or 480 microg) as primary prophylaxis of severe neutropenia. RESULTS: The results of the studies in healthy volunteers confirm the comparability of the test and reference products with respect to their pharmacodynamics and pharmacokinetics. Confidence intervals were within the predefined equivalence boundaries. In the phase III study in breast cancer patients, the administration of Zarzio was efficacious and safe, triggering no immunogenicity. CONCLUSION: The results of these studies demonstrate the biosimilarity of Zarzio with its reference product Neupogen.
RCT Entities:
BACKGROUND: Zarzio, a new recombinant humangranulocyte colony-stimulating factor (filgrastim), was evaluated in healthy volunteers and neutropenicpatients in phase I and III studies. PATIENTS AND METHODS: Healthy volunteers in randomized, two-period crossover studies received single- and multiple-dose s.c. injections of 1 microg/kg (n = 24), 2.5 microg/kg (n = 28), 5 microg/kg (n = 28), or 10 microg/kg (n = 40), as well as single-dose i.v. infusions of 5 microg/kg (n = 26), of Zarzio or the reference product (Neupogen). Filgrastim serum levels were monitored; pharmacodynamic parameters were absolute neutrophil count (all studies) and CD34(+) cells (multiple-dose studies). Supportive efficacy and safety data were obtained from an open phase III study in 170 breast cancerpatients undergoing four cycles of doxorubicin and docetaxel (Taxotere) chemotherapy, receiving Zarzio (300 or 480 microg) as primary prophylaxis of severe neutropenia. RESULTS: The results of the studies in healthy volunteers confirm the comparability of the test and reference products with respect to their pharmacodynamics and pharmacokinetics. Confidence intervals were within the predefined equivalence boundaries. In the phase III study in breast cancerpatients, the administration of Zarzio was efficacious and safe, triggering no immunogenicity. CONCLUSION: The results of these studies demonstrate the biosimilarity of Zarzio with its reference product Neupogen.
Authors: Cornelius F Waller; Renger G Tiessen; Tracey E Lawrence; Andrew Shaw; Mark Shiyao Liu; Rajiv Sharma; Mark Baczkowski; Mudgal A Kothekar; Catherine E Micales; Abhijit Barve; Gopinath M Ranganna; Eduardo J Pennella Journal: J Cancer Res Clin Oncol Date: 2018-04-18 Impact factor: 4.553
Authors: Pere Gascón; Matti Aapro; Heinz Ludwig; Carsten Bokemeyer; Mario Boccadoro; Matthew Turner; Kris Denhaerynck; Karen MacDonald; Ivo Abraham Journal: Support Care Cancer Date: 2015-08-27 Impact factor: 3.603
Authors: Isabel Puértolas; Alberto Frutos Pérez-Surio; María Aránzazu Alcácera; Raquel Andrés; María Del Tránsito Salvador Journal: Eur J Clin Pharmacol Date: 2017-11-19 Impact factor: 2.953